Adding genetic testing to the evaluation of pediatric patients with neurodevelopmental disorders (NDD) resulted in more individualized care.

Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin Appearance Observed in Pediatric Study after Only ...

Management Anticipates That it has Sufficiently Addressed the FDA’s Concerns to Mitigate the Need for a Clinical Data Request ...

Holoclara has completed its first Good Manufacturing Practice (GMP) batch of HC002, which will be used in the Phase 1 ...

T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx ® Instruments to its European (EU ...

Significant Improvement in Skin Appearance Observed in Pediatric Study after Only 12 Days of Dosing with QRX003 ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP ...

The test used two synovial fluid biomarkers to accurately differentiate osteoarthritis from inflammatory arthritis, but its ...

GP practices are facing confusion over different approaches to asthma diagnosis set out in the QOF and in the new UK joint ...

Differences between a patient’s true normal range and the population-based reference interval can create problems for doctors ...

Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical lab Clinical mass ...